

## CLAIMS

1. An isolated polypeptide comprising at least an immunogenic portion of a lung tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(a) sequences recited in SEQ ID NO: 1, 11-13, 15, 20, 23-27, 29, 30, 33, 34, 39, 41, 43-46, 51, 52, 57, 58, 60, 62, 65-67, 69-71, 74, 76, 79, 80, 84, 86, 89-92, 95, 97, 98, 101, 110, 111, 113-119, 121-128, 130-134, 136, 138, 139, 141, 143, 146-151, 153, 154, 157-160, 162-164, 167-178, 180, 181, 183, 186-190, 192, 193, 195-220, 224, 226-231, 234, 236, 237, 240, 241, 244-246, 248, 254, 255, 261, 262, 266, 270, 275, 280, 282, 283, 288, 289, 290, 292, 295, 301, 303, 304, 309, 311, 341-782, 784 and 785;

(b) sequences that hybridize to a sequence of SEQ ID NO: 1, 11-13, 15, 20, 23-27, 29, 30, 33, 34, 39, 41, 43-46, 51, 52, 57, 58, 60, 62, 65-67, 69-71, 74, 76, 79, 80, 84, 86, 89-92, 95, 97, 98, 101, 110, 111, 113-119, 121-128, 130-134, 136, 138, 139, 141, 143, 146-151, 153, 154, 157-160, 162-164, 167-178, 180, 181, 183, 186-190, 192, 193, 195-220, 224, 226-231, 234, 236, 237, 240, 241, 244-246, 248, 254, 255, 261, 262, 266, 270, 275, 280, 282, 283, 288, 289, 290, 292, 295, 301, 303, 304, 309, 311, 341-782, 784 and 785 under moderately stringent conditions; and

(c) a complement of a sequence of (a) or (b).

2. An isolated polypeptide according to claim 1, wherein the polypeptide comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NO: 1, 11-13, 15, 20, 23-27, 29, 30, 33, 34, 39, 41, 43-46, 51, 52, 57, 58, 60, 62, 65-67, 69-71, 74, 76, 79, 80, 84, 86, 89-92, 95, 97, 98, 101, 110, 111, 113-119, 121-128, 130-134, 136, 138, 139, 141, 143, 146-151, 153, 154, 157-160, 162-164, 167-178, 180, 181, 183, 186-190, 192, 193, 195-220, 224, 226-231, 234, 236, 237, 240, 241, 244-246, 248, 254, 255, 261, 262, 266, 270, 275, 280, 282, 283, 288, 289, 290, 292, 295, 301, 303, 304, 309, 311, 341-782, 784 and 785 or a complement of any of the foregoing polynucleotide sequences.

3. An isolated polypeptide comprising a sequence recited in any one of SEQ

ID NO: 786 and 787.

4. An isolated polynucleotide encoding at least 15 amino acid residues of a lung tumor protein, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antisera is not substantially diminished, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in any one of SEQ ID NO: 1, 11-13, 15, 20, 23-27, 29, 30, 33, 34, 39, 41, 43-46, 51, 52, 57, 58, 60, 62, 65-67, 69-71, 74, 76, 79, 80, 84, 86, 89-92, 95, 97, 98, 101, 110, 111, 113-119, 121-128, 130-134, 136, 138, 139, 141, 143, 146-151, 153, 154, 157-160, 162-164, 167-178, 180, 181, 183, 186-190, 192, 193, 195-220, 224, 226-231, 234, 236, 237, 240, 241, 244-246, 248, 254, 255, 261, 262, 266, 270, 275, 280, 282, 283, 288, 289, 290, 292, 295, 301, 303, 304, 309, 311, 341-782, 784 and 785 or a complement of any of the foregoing sequences.

5. An isolated polynucleotide encoding a lung tumor protein, or a variant thereof, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide comprising a sequence recited in any one of SEQ ID NO: 1, 11-13, 15, 20, 23-27, 29, 30, 33, 34, 39, 41, 43-46, 51, 52, 57, 58, 60, 62, 65-67, 69-71, 74, 76, 79, 80, 84, 86, 89-92, 95, 97, 98, 101, 110, 111, 113-119, 121-128, 130-134, 136, 138, 139, 141, 143, 146-151, 153, 154, 157-160, 162-164, 167-178, 180, 181, 183, 186-190, 192, 193, 195-220, 224, 226-231, 234, 236, 237, 240, 241, 244-246, 248, 254, 255, 261, 262, 266, 270, 275, 280, 282, 283, 288, 289, 290, 292, 295, 301, 303, 304, 309, 311, 341-782, 784 and 785 or a complement of any of the foregoing sequences.

6. An isolated polynucleotide comprising a sequence recited in any one of SEQ ID NO: 1, 11-13, 15, 20, 23-27, 29, 30, 33, 34, 39, 41, 43-46, 51, 52, 57, 58, 60, 62, 65-67, 69-71, 74, 76, 79, 80, 84, 86, 89-92, 95, 97, 98, 101, 110, 111, 113-119, 121-128, 130-134, 136, 138, 139, 141, 143, 146-151, 153, 154, 157-160, 162-164, 167-178, 180, 181, 183, 186-190, 192, 193, 195-220, 224, 226-231, 234, 236, 237, 240, 241, 244-246, 248, 254, 255, 261, 262, 266, 270, 275, 280, 282, 283, 288, 289, 290, 292, 295, 301, 303, 304, 309, 311, 341-782, 784 and

7. An isolated polynucleotide comprising a sequence that hybridizes to a sequence recited in any one of SEQ ID NO: 1, 11-13, 15, 20, 23-27, 29, 30, 33, 34, 39, 41, 43-46, 51, 52, 57, 58, 60, 62, 65-67, 69-71, 74, 76, 79, 80, 84, 86, 89-92, 95, 97, 98, 101, 110, 111, 113-119, 121-128, 130-134, 136, 138, 139, 141, 143, 146-151, 153, 154, 157-160, 162-164, 167-178, 180, 181, 183, 186-190, 192, 193, 195-220, 224, 226-231, 234, 236, 237, 240, 241, 244-246, 248, 254, 255, 261, 262, 266, 270, 275, 280, 282, 283, 288, 289, 290, 292, 295, 301, 303, 304, 309, 311, 341-782, 784 and 785 under moderately stringent conditions.

9. An expression vector comprising a polynucleotide according to any one of claims 4-8.

11. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a lung tumor protein that comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NO: 1, 11-13, 15, 20, 23-27, 29, 30, 33, 34, 39, 41, 43-46, 51, 52, 57, 58, 60, 62, 65-67, 69-71, 74, 76, 79, 80, 84, 86, 89-92, 95, 97, 98, 101, 110, 111, 113-119, 121-128, 130-134, 136, 138, 139, 141, 143, 146-151, 153, 154, 157-160, 162-164, 167-178, 180, 181, 183, 186-190, 192, 193, 195-220, 224, 226-231, 234, 236, 237, 240, 241, 244-246, 248, 254, 255, 261, 262, 266, 270, 275, 280, 282, 283, 288, 289, 290, 292, 295, 301, 303, 304, 309, 311, 341-782, 784 and 785 or a complement of any of the foregoing polynucleotide sequences.

12. A fusion protein comprising at least one polypeptide according to claim 1.

13. A fusion protein according to claim 12, wherein the fusion protein comprises an expression enhancer that increases expression of the fusion protein in a host cell transfected with a polynucleotide encoding the fusion protein.

14. A fusion protein according to claim 12, wherein the fusion protein comprises a T helper epitope that is not present within the polypeptide of claim 1.

15. A fusion protein according to claim 12, wherein the fusion protein comprises an affinity tag.

16. An isolated polynucleotide encoding a fusion protein according to claim 12.

17. A pharmaceutical composition comprising a physiologically acceptable carrier and at least one component selected from the group consisting of:

- (a) a polypeptide according to claim 1;
- (b) a polynucleotide according to claim 4;
- (c) an antibody according to claim 11;
- (d) a fusion protein according to claim 12; and
- (e) a polynucleotide according to claim 16.

18. A vaccine comprising an immunostimulant and at least one component selected from the group consisting of:

- (a) a polypeptide according to claim 1;
- (b) a polynucleotide according to claim 4;
- (c) an antibody according to claim 11;
- (d) a fusion protein according to claim 12; and
- (e) a polynucleotide according to claim 16.

03040506070809101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899

19. A vaccine according to claim 18, wherein the immunostimulant is an adjuvant.
20. A vaccine according to claim 18, wherein the immunostimulant induces a predominantly Type I response.
21. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a pharmaceutical composition according to claim 17.
22. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a vaccine according to claim 20.
23. A pharmaceutical composition comprising an antigen-presenting cell that expresses a polypeptide according to claim 1, in combination with a pharmaceutically acceptable carrier or excipient.
24. A pharmaceutical composition according to claim 23, wherein the antigen presenting cell is a dendritic cell or a macrophage.
25. A vaccine comprising an antigen-presenting cell that expresses a polypeptide according to claim 1, in combination with an immunostimulant.
26. A vaccine according to claim 25, wherein the immunostimulant is an adjuvant.
27. A vaccine according to claim 25, wherein the immunostimulant induces a predominantly Type I response.
28. A vaccine according to claim 25, wherein the antigen-presenting cell is a

dendritic cell.

29. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of an antigen-presenting cell that expresses a polypeptide encoded by a polynucleotide recited in any one of SEQ ID NO: 1, 11-13, 15, 20, 23-27, 29, 30, 33, 34, 39, 41, 43-46, 51, 52, 57, 58, 60, 62, 65-67, 69-71, 74, 76, 79, 80, 84, 86, 89-92, 95, 97, 98, 101, 110, 111, 113-119, 121-128, 130-134, 136, 138, 139, 141, 143, 146-151, 153, 154, 157-160, 162-164, 167-178, 180, 181, 183, 186-190, 192, 193, 195-220, 224, 226-231, 234, 236, 237, 240, 241, 244-246, 248, 254, 255, 261, 262, 266, 270, 275, 280, 282, 283, 288, 289, 290, 292, 295, 301, 303, 304, 309, 311, 341-782, 784 and 785, and thereby inhibiting the development of a cancer in the patient.

30. A method according to claim 29, wherein the antigen-presenting cell is a dendritic cell.

31. A method according to any one of claims 21, 22 and 29, wherein the cancer is lung cancer.

32. A method for removing tumor cells from a biological sample, comprising contacting a biological sample with T cells that specifically react with a lung tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:

(i) polynucleotides recited in any one of SEQ ID NO: 1-782, 784, 785 and 788; and

(ii) complements of the foregoing polynucleotides;

wherein the step of contacting is performed under conditions and for a time sufficient to permit the removal of cells expressing the antigen from the sample.

33. A method according to claim 32, wherein the biological sample is blood or a fraction thereof.

34. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient a biological sample treated according to the method of claim 50.

35. A method for stimulating and/or expanding T cells specific for a lung tumor protein, comprising contacting T cells with at least one component selected from the group consisting of:

- (i) a polypeptide according to claim 1;
- (ii) a polypeptide encoded by a polynucleotide comprising a sequence provided in any one of SEQ ID NO: 1-782, 784, 785 and 788;
- (iii) a polynucleotide encoding a polypeptide of (i) or (ii); and
- (iv) an antigen presenting cell that expresses a polypeptide of (i) or (ii), under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells.

36. An isolated T cell population, comprising T cells prepared according to the method of claim 35.

37. A method for inhibiting the development of a cancer in a patient, comprising administering to a patient an effective amount of a T cell population according to claim 36.

38. A method for inhibiting the development of a cancer in a patient, comprising the steps of:

- (a) incubating CD4<sup>+</sup> and/or CD8<sup>+</sup> T cells isolated from a patient with at least one component selected from the group consisting of:
  - (i) a polypeptide according to claim 1;
  - (ii) a polypeptide encoded by a polynucleotide comprising a sequence of any one of SEQ ID NO: 1-782, 784, 785 and 788;

- (b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting the development of a cancer in the patient.

(a) incubating CD4<sup>+</sup> and/or CD8<sup>+</sup> T cells isolated from a patient with at least one component selected from the group consisting of:

- (b) cloning at least one proliferated cell to provide cloned T cells; and
- (c) administering to the patient an effective amount of the cloned T cells, and thereby inhibiting the development of a cancer in the patient.

40. A method for determining the presence or absence of a cancer in a patient, comprising the steps of:

- (a) contacting a biological sample obtained from a patient with a binding agent that binds to a lung tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence selected from the group consisting of:
- (i) polynucleotides recited in any one of SEQ ID NO: 1-782, 784, 785 and 788; and
  - (ii) complements of the foregoing polynucleotides;
- (b) detecting in the sample an amount of polypeptide that binds to the binding agent; and



(c) comparing the amount of polypeptide to a predetermined cut-off value,

41. A method according to claim 40, wherein the binding agent is an antibody.

42. A method according to claim 43, wherein the antibody is a monoclonal

43. A method according to claim 40, wherein the cancer is lung cancer.

44. A method for monitoring the progression of a cancer in a patient,

(a) contacting a biological sample obtained from a patient at a first point in time with a binding agent that binds to a lung tumor protein, wherein the tumor protein has an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of Claims 1-10, 12-14, 16-18, 20-22, 24-26, 28-30, 32-34, 36-38, 40-42, 44-46, 48-50, 52-54, 56-58, 60-62, 64-66, 68-70, 72-74, 76-78, 80-82, 84-86, 88-90, 92-94, 96-98, 100-102, 104-106, 108-110, 112-114, 116-118, 120-122, 124-126, 128-130, 132-134, 136-138, 140-142, 144-146, 148-150, 152-154, 156-158, 160-162, 164-166, 168-170, 172-174, 176-178, 180-182, 184-186, 188-190, 192-194, 196-198, 200-202, 204-206, 208-210, 212-214, 216-218, 220-222, 224-226, 228-230, 232-234, 236-238, 240-242, 244-246, 248-250, 252-254, 256-258, 260-262, 264-266, 268-270, 272-274, 276-278, 280-282, 284-286, 288-290, 292-294, 296-298, 300-302, 304-306, 308-310, 312-314, 316-318, 320-322, 324-326, 328-330, 332-334, 336-338, 340-342, 344-346, 348-350, 352-354, 356-358, 360-362, 364-366, 368-370, 372-374, 376-378, 380-382, 384-386, 388-390, 392-394, 396-398, 400-402, 404-406, 408-410, 412-414, 416-418, 420-422, 424-426, 428-430, 432-434, 436-438, 440-442, 444-446, 448-450, 452-454, 456-458, 460-462, 464-466, 468-470, 472-474, 476-478, 480-482, 484-486, 488-490, 492-494, 496-498, 500-502, 504-506, 508-510, 512-514, 516-518, 520-522, 524-526, 528-530, 532-534, 536-538, 540-542, 544-546, 548-550, 552-554, 556-558, 560-562, 564-566, 568-570, 572-574, 576-578, 580-582, 584-586, 588-590, 592-594, 596-598, 600-602, 604-606, 608-610, 612-614, 616-618, 620-622, 624-626, 628-630, 632-634, 636-638, 640-642, 644-646, 648-650, 652-654, 656-658, 660-662, 664-666, 668-670, 672-674, 676-678, 680-682, 684-686, 688-690, 692-694, 696-698, 700-702, 704-706, 708-710, 712-714, 716-718, 720-722, 724-726, 728-730, 732-734, 736-738, 740-742, 744-746, 748-750, 752-754, 756-758, 760-762, 764-766, 768-770, 772-774, 776-778, 780-782, 784-786, 788-790, 792-794, 796-798, 800-802, 804-806, 808-810, 812-814, 816-818, 820-822, 824-826, 828-830, 832-834, 836-838, 840-842, 844-846, 848-850, 852-854, 856-858, 860-862, 864-866, 868-870, 872-874, 876-878, 880-882, 884-886, 888-890, 892-894, 896-898, 900-902, 904-906, 908-910, 912-914, 916-918, 920-922, 924-926, 928-930, 932-934, 936-938, 940-942, 944-946, 948-950, 952-954, 956-958, 960-962, 964-966, 968-970, 972-974, 976-978, 980-982, 984-986, 988-990, 992-994, 996-998, 1000-1002, 1004-1006, 1008-1010, 1012-1014, 1016-1018, 1020-1022, 1024-1026, 1028-1030, 1032-1034, 1036-1038, 1040-1042, 1044-1046, 1048-1050, 1052-1054, 1056-1058, 1060-1062, 1064-1066, 1068-1070, 1072-1074, 1076-1078, 1080-1082, 1084-1086, 1088-1090, 1092-1094, 1096-1098, 1100-1102, 1104-1106, 1108-1110, 1112-1114, 1116-1118, 1120-1122, 1124-1126, 1128-1130, 1132-1134, 1136-1138, 1140-1142, 1144-1146, 1148-1150, 1152-1154, 1156-1158, 1160-1162, 1164-1166, 1168-1170, 1172-1174, 1176-1178, 1180-1182, 1184-1186, 1188-1190, 1192-1194, 1196-1198, 1200-1202, 1204-1206, 1208-1210, 1212-1214, 1216-1218, 1220-1222, 1224-1226, 1228-1230, 1232-1234, 1236-1238, 1240-1242, 1244-1246, 1248-1250, 1252-1254, 1256-1258, 1260-1262, 1264-1266, 1268-1270, 1272-1274, 1276-1278, 1280-1282, 1284-1286, 1288-1290, 1292-1294, 1296-1298, 1300-1302, 1304-1306, 1308-1310, 1312-1314, 1316-1318, 1320-1322, 1324-1326, 1328-1330, 1332-1334, 1336-1338, 1340-1342, 1344-1346, 1348-1350, 1352-1354, 1356-1358, 1360-1362, 1364-1366, 1368-1370, 1372-1374, 1376-1378, 1380-1382, 1384-1386, 1388-1390, 1392-1394, 1396-1398, 1400-1402, 1404-1406, 1408-1410, 1412-1414, 1416-1418, 1420-1422, 1424-1426, 1428-1430, 1432-1434, 1436-1438, 1440-1442, 1444-1446, 1448-1450, 1452-1454, 1456-1458, 1460-1462, 1464-1466, 1468-1470, 1472-1474, 1476-1478, 1480-1482, 1484-1486, 1488-1490, 1492-1494, 1496-1498, 1500-1502, 1504-1506, 1508-1510, 1512-1514, 1516-1518, 1520-1522, 1524-1526, 1528-1530, 1532-1534, 1536-1538, 1540-1542, 1544-1546, 1548-1550, 1552-1554, 1556-1558, 1560-1562, 1564-1566, 1568-1570, 1572-1574, 1576-1578, 1580-1582, 1584-1586, 1588-1590, 1592-1594, 1596-1598, 1600-1602, 1604-1606, 1608-1610, 1612-1614, 1616-1618, 1620-1622, 1624-1626, 1628-1630, 1632-1634, 1636-1638, 1640-1642, 1644-1646, 1648-1650, 1652-1654, 1656-1658, 1660-1662, 1664-1666, 1668-1670, 1672-1

(b) detecting in the sample an amount of polypeptide that binds to the binding

(c) repeating steps (a) and (b) using a biological sample obtained from the

(d) comparing the amount of polypeptide detected in step (c) to the amount in step (b) and therefrom monitoring the progression of the cancer in the patient.

45. A method according to claim 44, wherein the binding agent is an antibody.

46. A method according to claim 45, wherein the antibody is a monoclonal

47. A method according to claim 44, wherein the cancer is a lung cancer.

(a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a lung tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NO: 1-782, 784, 785 and 788 or a complement of any of the foregoing polynucleotides;

(c) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence or absence of a cancer in the patient.

50. A method according to claim 48, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a hybridization assay.

(a) contacting a biological sample obtained from a patient with an oligonucleotide that hybridizes to a polynucleotide that encodes a lung tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NO: 1-782, 784, 785 and 788 or a complement of any of the foregoing polynucleotides;

(c) repeating steps (a) and (b) using a biological sample obtained from the

(d) comparing the amount of polynucleotide detected in step (c) to the amount detected in step (b) and therefrom monitoring the progression of the cancer in the patient.

53. A method according to claim 51, wherein the amount of polynucleotide that hybridizes to the oligonucleotide is determined using a hybridization assay.

(a) one or more antibodies according to claim 11; and

55. A kit according to claim 54, wherein the antibodies are immobilized on a solid support.

56. A kit according to claim 54, wherein the detection reagent comprises an anti-immunoglobulin, protein G, protein A or lectin.

57. A kit according to claim 54, wherein the reporter group is selected from the group consisting of radioisotopes, fluorescent groups, luminescent groups, enzymes, biotin and dye particles.

58. An oligonucleotide comprising 10 to 40 contiguous nucleotides that hybridize under moderately stringent conditions to a polynucleotide that encodes a lung tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide sequence recited in any one of SEQ ID NO: 1, 11-13, 15, 20, 23-27, 29, 30, 33, 34, 39, 41, 43-46, 51, 52, 57, 58, 60, 62, 65-67, 69-71, 74, 76, 79, 80, 84, 86, 89-92, 95, 97, 98, 101, 110, 111, 113-119, 121-128, 130-134, 136, 138, 139, 141, 143, 146-151, 153, 154, 157-160,

162-164, 167-178, 180, 181, 183, 186-190, 192, 193, 195-220, 224, 226-231, 234, 236, 237, 240, 241, 244-246, 248, 254, 255, 261, 262, 266, 270, 275, 280, 282, 283, 288, 289, 290, 292, 295, 301, 303, 304, 309, 311, 341-782, 784 and 785 or a complement of any of the foregoing polynucleotides.

59. A oligonucleotide according to claim 58, wherein the oligonucleotide comprises 10-40 contiguous nucleotides recited in any one of SEQ ID NO: 1, 11-13, 15, 20, 23-27, 29, 30, 33, 34, 39, 41, 43-46, 51, 52, 57, 58, 60, 62, 65-67, 69-71, 74, 76, 79, 80, 84, 86, 89-92, 95, 97, 98, 101, 110, 111, 113-119, 121-128, 130-134, 136, 138, 139, 141, 143, 146-151, 153, 154, 157-160, 162-164, 167-178, 180, 181, 183, 186-190, 192, 193, 195-220, 224, 226-231, 234, 236, 237, 240, 241, 244-246, 248, 254, 255, 261, 262, 266, 270, 275, 280, 282, 283, 288, 289, 290, 292, 295, 301, 303, 304, 309, 311, 341-782, 784 and 785.

60. A diagnostic kit, comprising:

- (a) an oligonucleotide according to claim 59; and
- (b) a diagnostic reagent for use in a polymerase chain reaction or hybridization assay.

add a1